Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 30;9(4):e002189. doi: 10.1136/jitc-2020-002189

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The expression of co-inhibitory receptors on T cells. (A) Cumulative data showing percentages of CD8⁺ and CD4⁺ T cells in peripheral blood mononuclear cells (PBMCs) of patients with chronic lymphocytic leukemia (CLL) versus healthy controls (HCs). (B) Representative flow cytometry plots of CD160⁺CD8⁺ T cells, and (C) CD160⁺CD4⁺ T cells in the blood and bone marrow (BM) of patients with CLL versus HC blood. (D) Cumulative data of percentages of CD160⁺ among CD8⁺ T cells, and (E) CD4⁺ T cells in CLL (blood and BM) versus HC blood. (F) Histogram plots of CD160 expression on CD8⁺, and (G) CD4⁺ T cells measured by the mean fluorescence intensity (MFI), and (H) cumulative data in CD8⁺/CD4⁺T cells of patients with CLL versus HCs. (I) Expression of CD160 mRNA level in CD8⁺ T cells of patients with CLL (PBMCs) relative to HCs. (J) Representative flow cytometry plots, and (K) cumulative data of percentages of CD8⁺ and CD4⁺ T cells expressing intracytoplasmic (ICS) CD160 in PBMCs of patients with CLL versus HCs. (L) Representative flow cytometry plots, and (M) cumulative data of percentages of HVEM⁺CD8⁺ and HVEM⁺CD4⁺ T cells in patients with CLL versus HCs. (N) Cumulative data of percentages of CD8⁺, and (O) CD4⁺ T cells expressing surface expression of 2B4, TIGIT, PD-1, BTLA, Galectin-9 (GAL-9) and TIM-3 on CD8⁺ T cells in patients with CLL (blood and BM) versus HC blood. Each dot represents data from a single patient with CLL or HC. Figure 1H and 1L from six human subjects/group. BTLA, B- and T-lymphocyte attenuator; HVEM, herpesvirus entry mediator; TIGIT, T cell immunoreceptor with Ig and ITIM domains; TIM-3, T-cell immunoglobin ad mucin-domain containing-3.